Although attention on COVID-19 vaccine and therapeutic development has waned since the height of the pandemic, research activity remains steady as the industry tries to stay ahead of new variants, continues to reduce COVID-19-related hospitalizations and mortality and grapples with long COVID.
Not all will make it to market, but the lessons continue to be folded into programs for other therapeutic areas and have accelerated advancement in areas such as mRNA.
